Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Arnaud Méjean, ASCO 2018 – Cytoreductive nephrectomy and the CARMENA trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 12th 2018

Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial.

1. What is the current role of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma? (0:11)

2. How did the advent of targeted therapies affect the use of cytoreductive nephrectomy? (0:32)

3. Could you tell us a little about the design of the CARMENA clinical trial? (0:58)

4. What were the findings of this study? (2:02)

5. What patients are most likely to benefit from this approach? (3:08)

Speaker disclosures: Arnaud Méjean has nothing to disclose in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup